Evidence map›Paper›PMID 37297018›Full record

ArticleCancers2023

Risk of Second Primary Malignancies in Melanoma Survivors: A Population-Based Study.

Javier Antoñanzas, Ana Morello-Vicente, Gloria Maria Garnacho-Saucedo, Pedro Redondo, Leyre Aguado-Gil, Rafael Salido-Vallejo

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. International Dermoscopy Society consensus recommendations for the management of lentigo maligna.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Javier AntoñanzasDermatology Department, University Clinic of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-8372-5044
Ana Morello-VicenteDermatology Department, University Clinic of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-9342-9698
Gloria Maria Garnacho-SaucedoDermatology Department, Reina Sofía University Hospital, 14004 Cordoba, Spain.
Pedro RedondoDermatology Department, University Clinic of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-7899-2511
Leyre Aguado-GilDermatology Department, University Clinic of Navarra, 31008 Pamplona, Spain.
Rafael Salido-VallejoDermatology Department, University Clinic of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-7210-8959
Clinica Universidad de Navarra · ESHospital Universitario Reina Sofía · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Introduction: The association between melanoma (MM) and the occurrence of second primary neoplasms (SPNs) has been extensively studied, with reported incidence rates ranging from 1.5% to 20%. This study aims to evaluate the occurrence of SPNs in patients with a history of primary MM and to describe the factors that make the risk higher in our population. (2) Material and Methods: We conducted a prospective cohort study and calculated the incidence rates and relative risks (RR) for the development of different SPNs in 529 MM survivors from 1 January 2005 to 1 August 2021. Survival and mortality rates were obtained, and the Cox proportional hazards model was used to determine the demographic and MM-related factors that influence the overall risk. (3) Results: Among the 529 patients included, 89 were diagnosed with SPNs (29 prior to MM diagnosis, 11 synchronous, and 49 after MM), resulting in 62 skin tumors and 37 solid organ tumors. The estimated probability of developing SPNs after MM diagnosis was 4.1% at 1 year, 11% at 5 years, and 19% at 10 years. Older age, primary MM location on the face or neck, and histologic subtype of lentigo maligna mm were significantly associated with a higher risk of SPNs. (4) Conclusions: In our population, the risk of developing SPNs was higher in patients with primary MM located on the face and neck and with the histological subtype of lentigo maligna-MM. Age also independently influences the risk. Understanding these hazard factors can aid in the development of MM guidelines with specific follow-up recommendations for individuals with the highest risk.

Indexed as

melanomaprognosisrisk factorssecond primary neoplasmssurvival

Identifiers

PMID37297018
PMCPMC10252898
OpenAlexW4379536446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.